Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Alaska Permanent Fund Corp

Alaska Permanent Fund Corp grew its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 17.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 30,167 shares of the pharmaceutical company’s stock after buying an additional 4,497 shares during the quarter. Alaska Permanent Fund Corp’s holdings in Vertex Pharmaceuticals were worth $12,275,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Geneos Wealth Management Inc. increased its stake in Vertex Pharmaceuticals by 39.4% during the third quarter. Geneos Wealth Management Inc. now owns 191 shares of the pharmaceutical company’s stock worth $66,000 after acquiring an additional 54 shares during the last quarter. Global Retirement Partners LLC lifted its stake in Vertex Pharmaceuticals by 28.4% during the third quarter. Global Retirement Partners LLC now owns 1,194 shares of the pharmaceutical company’s stock valued at $421,000 after purchasing an additional 264 shares during the last quarter. Ziegler Capital Management LLC lifted its position in Vertex Pharmaceuticals by 8.1% in the 3rd quarter. Ziegler Capital Management LLC now owns 16,118 shares of the pharmaceutical company’s stock worth $5,605,000 after buying an additional 1,208 shares in the last quarter. Capital Investment Advisors LLC bought a new position in shares of Vertex Pharmaceuticals during the 3rd quarter valued at $293,000. Finally, Flagship Harbor Advisors LLC grew its stake in Vertex Pharmaceuticals by 4.7% in the 3rd quarter. Flagship Harbor Advisors LLC now owns 1,571 shares of the pharmaceutical company’s stock valued at $546,000 after buying an additional 70 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Analyst Ratings Changes

VRTX has been the subject of several analyst reports. Canaccord Genuity Group cut shares of Vertex Pharmaceuticals from a “hold” rating to a “sell” rating and lifted their price target for the stock from $332.00 to $379.00 in a research report on Wednesday, January 24th. Evercore ISI upgraded shares of Vertex Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $438.00 price objective on the stock in a research note on Thursday, April 11th. Truist Financial raised their price target on shares of Vertex Pharmaceuticals from $456.00 to $508.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. Wolfe Research started coverage on shares of Vertex Pharmaceuticals in a report on Thursday, February 15th. They set an “outperform” rating and a $515.00 price objective on the stock. Finally, Canaccord Genuity Group restated a “sell” rating and issued a $371.00 price objective on shares of Vertex Pharmaceuticals in a research note on Friday, April 12th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $429.45.

Vertex Pharmaceuticals Price Performance

Vertex Pharmaceuticals stock traded down $2.97 during mid-day trading on Thursday, reaching $397.79. 53,337 shares of the company’s stock traded hands, compared to its average volume of 1,225,375. Vertex Pharmaceuticals Incorporated has a 12-month low of $316.43 and a 12-month high of $448.40. The company has a market cap of $102.81 billion, a price-to-earnings ratio of 28.85, a PEG ratio of 1.91 and a beta of 0.35. The company has a quick ratio of 3.78, a current ratio of 3.99 and a debt-to-equity ratio of 0.02. The stock has a 50 day moving average of $412.66 and a two-hundred day moving average of $398.38.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 EPS for the quarter, beating the consensus estimate of $3.85 by $0.35. The business had revenue of $2.52 billion during the quarter, compared to analyst estimates of $2.50 billion. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. During the same period in the prior year, the firm posted $3.33 earnings per share. Equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current year.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, EVP Amit Sachdev sold 3,222 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $1,354,013.28. Following the completion of the transaction, the executive vice president now directly owns 74,364 shares of the company’s stock, valued at approximately $31,250,727.36. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CAO Kristen Ambrose sold 1,374 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $420.24, for a total transaction of $577,409.76. Following the completion of the sale, the chief accounting officer now owns 9,676 shares of the company’s stock, valued at $4,066,242.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Amit Sachdev sold 3,222 shares of Vertex Pharmaceuticals stock in a transaction on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the completion of the transaction, the executive vice president now directly owns 74,364 shares of the company’s stock, valued at approximately $31,250,727.36. The disclosure for this sale can be found here. Insiders have sold a total of 12,381 shares of company stock valued at $5,203,249 in the last 90 days. 0.20% of the stock is owned by insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.